Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PKTX | 8-K | mixed | 5/10 | ProtoKinetix filed an 8-K reporting board changes (resignation of Edward McDonough, appointment of three new directors i | Jun 17, 2026 |
| LIFD | 8-K | neutral | 2/10 | Director Richard Morrissy resigned from LFTD Partners' board effective June 14, 2026, citing health concerns. The filing | Jun 17, 2026 |
| KYMR | 144 | bearish | 4/10 | Three Form 144 filings from Kymera Therapeutics on June 17, 2026, signal intent to sell by director Bruce Booth (11,741 | Jun 17, 2026 |
| PTHS | CLUSTER | bullish | 6/10 | Director Todd C. Davis purchased $986K of PTHS stock at $27.80, representing ~1% of market cap, while another director s | Jun 17, 2026 |
| VTGN | 8-K | neutral | 2/10 | Two board members, Margaret FitzPatrick and Dr. Joanne Curley, notified Vistagen they will not stand for re-election at | Jun 17, 2026 |
| EXOZ | 8-K | bearish | 6/10 | EXOZYMES INC. closed its underwritten public offering of common stock and warrants, including partial exercise of the ov | Jun 17, 2026 |
| ABOS | CLUSTER | neutral | 2/10 | Two directors at Acumen Pharmaceuticals sold a combined $29K in open-market shares over a 7-day window, representing ~0. | Jun 17, 2026 |
| QURE | CLUSTER | neutral | 3/10 | Nine insiders at uniQure N.V. (QURE) sold a total of $1.2M in shares over a 7-day window, representing approximately 0.0 | Jun 17, 2026 |
| ARDX | 8-K | neutral | 3/10 | Ardelyx stockholders approved an amendment to the 2014 Equity Incentive Award Plan, increasing the share reserve by 9 mi | Jun 17, 2026 |
| MSLE | PRESS-RELEASE | neutral | 2/10 | Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, with all director nominees elected an | Jun 17, 2026 |
| MSLE | 6-K | neutral | 2/10 | Satellos Bioscience filed a 6-K reporting voting results from its June 17, 2026 annual meeting. All nine director nomine | Jun 17, 2026 |
| KROS | CLUSTER | neutral | 2/10 | Two KROS directors made minor opposing trades: Bienaime purchased $10K worth of shares while Newton sold $6K. Total insi | Jun 17, 2026 |
| BDRX | 6-K | neutral | 2/10 | Biodexa Pharmaceuticals PLC filed a 6-K reporting that its Annual General Meeting (AGM) on June 17, 2026 was adjourned d | Jun 17, 2026 |
| LEGN | 424B5 | neutral | 4/10 | Legend Biotech Corp is filing a preliminary prospectus supplement for a proposed $225,000,000 offering of American Depos | Jun 17, 2026 |
| CNEY | 6-K | neutral | 2/10 | CN Energy Group entered a Mutual Settlement Agreement with former CEO Steven Berman, resolving all disputes and claims f | Jun 17, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cas | Jun 17, 2026 |
| JAZZ | CLUSTER | neutral | 2/10 | Two Jazz Pharmaceuticals insiders (a director and the EVP & Chief Legal Officer) sold a combined $545K in open-market tr | Jun 17, 2026 |
| ODTX | 8-K | neutral | 4/10 | Odyssey Therapeutics reported Q1 2026 financial results with a net loss of $38.3M, essentially flat YoY, and no revenue | Jun 17, 2026 |
| CORT | 8-K | bullish | 6/10 | Corcept Therapeutics resubmitted its New Drug Application (NDA) to the FDA for relacorilant as a treatment for Cushing's | Jun 17, 2026 |
| ABEO | CLUSTER | neutral | 4/10 | Five ABEO insiders, including the CEO and CFO, sold a total of $407K in shares over a 7-day window. The selling represen | Jun 17, 2026 |
| LNAI | 8-K | mixed | 5/10 | Lunai Bioworks issued a CEO letter updating on a first revenue-generating defense contract (undisclosed value), a Phase | Jun 17, 2026 |
| ANAB | 144 | bearish | 5/10 | Officer Dennis Mulroy filed a Form 144 to sell 850 shares (~$51k), but the filing also discloses a massive 3-month selli | Jun 17, 2026 |
| RIGL | 8-K | neutral | 4/10 | Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for | Jun 17, 2026 |
| ADTX | CLUSTER | bearish | 5/10 | Insider cluster at Aditxt (ADTX) shows mixed activity: HRT Financial LP bought ~$97.6K in two open-market purchases but | Jun 17, 2026 |
| MLYS | 144 | neutral | 2/10 | Officer David Rodman filed Form 144 to sell 4,584 shares of Mineralys Therapeutics (MLYS) at an estimated $114,600. The | Jun 17, 2026 |
| ICLR | 6-K | neutral | 2/10 | ICON plc filed a 6-K announcing its Q1 2026 earnings release and conference call schedule: results will be released afte | Jun 17, 2026 |
| KRRO | CLUSTER | neutral | 3/10 | Four senior insiders at Korro Bio (COO, CSO, SVP Finance, General Counsel) sold a total of $180K in open-market sales on | Jun 17, 2026 |
| DYN | CLUSTER | neutral | 2/10 | Three top executives (CEO, CMO, CCO) at Dyne Therapeutics sold a combined ~$68K in shares on June 16, 2026, the same day | Jun 17, 2026 |
| SAFX | 8-K | bullish | 5/10 | XCF Global terminated a $50M equity line of credit (ELOC) purchase agreement with Helena Global, releasing approximately | Jun 17, 2026 |
| QURE | 144 | neutral | 2/10 | Director Madhavan filed Form 144 to sell 11,685 ordinary shares (~$526K) under a 10b5-1 plan adopted March 16, 2026. Thi | Jun 17, 2026 |